课题基金 / 基金详情

Biocompatible Dendritic Polymers : In Vivo Applications

Biocompatible Dendritic Polymers : In Vivo Applications
生物相容性树枝状聚合物:体内应用
批准号:
6464591
负责人:
FRANCIS C. SZOKA
金额:
$36.07万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-01 至 2006-03-31

项目摘要

项目成果

FRANCIS C. SZOKA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We describe a new, robust and economical chemical approach to prepare modular biodegradable dendritic polymers with narrow polydispersities. These novel materials can potentially be used as polymeric drug carriers, in sustained drug delivery systems or to coat implantable bioengineered medical devices. We will test the hypothesis that dendritic polymeric drugs with the appropriate molecular weight, architecture, drug and bioreversible drug linkages, provide improved biodistribution properties that result in superior anti-cancer drug therapy compared to the parent drug. In specific aim number 1 we will devise flexible synthetic methods for the preparation of biocompatible dendritic carriers. We developed a new, rapid and low cost synthesis of these dendritic molecules that eliminate the need for the tedious purification steps required for most dendrimers. We will develop additional synthetic methods and optimize molecular architecture, functionality, and modularity that will greatly extend the versatility of this promising class of multivalent drug carriers for targeted drug delivery. In specific aim number 2, we will determine the effects of polymer mass and architecture on physico-chemical properties in solution and pharmacokinetic behavior in mice. The physical properties of these polymers will be determined using a combination of characterization techniques, including light scattering measurements, gel permeation chromatography, and STM. Subsequent in vitro and in vivo experiments will be conducted to determine the cellular uptake, pharmacokinetics, biodistribution and tumor uptake of attached materials in tumor-bearing mice. In specific aim number 3 we will determine the potency of polymeric- anticancer drugs against a human breast cancer in a xenograft solid tumor murine model as function of polymer attributes, targeting ligand, drug type, drug loading and drug release mechanism. It is anticipated that dendritic polymers with appropriate MW and architecture will better exploit the enhanced penetration and retention phenomenon found in solid tumors; hence lead to improved anti-tumor therapy. Success in this research will greatly improve our ability to design polymeric drug carriers that would be extremely difficult to prepare using other methods of polymer synthesis and that enable the optimization of the pharmacokinetic properties for a wide variety of targeted therapeutic and imaging applications.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
A new approach to heterofunctionalized dendrimers: a versatile triallyl chloride core.
异功能化树枝状聚合物的新方法:多功能三烯丙基氯核心。
DOI: 10.1021/ol0262993
发表时间: 2002
期刊: Organic letters
影响因子: 5.2
作者: [Grayson,ScottM, Fréchet,JeanMJ]
通讯作者: Fréchet,JeanMJ
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells
  • 批准号:
    8833239
  • 项目类别:
  • 资助金额:
    $29.89万
  • 财政年份:
    2015
  • 负责人:
    FRANCIS C. SZOKA
  • 依托单位:
Syngeneic Macrophages for Personalized Cancer Therapy
Improving Protein Delivery and Circulation via FcRn Ligands
Improving Protein Delivery and Circulation via FcRn Ligands
海外基金